Fate Therapeutics (FATE) Cantor Global Healthcare Conference 2025 summary

Strategic vision and technology

• Focus on making transformative CAR T-cell therapies broadly accessible using off-the-shelf, stem cell-derived products for oncology and autoimmune diseases.

• FT819, a CD19 CAR T-cell, is positioned as a differentiated, potent, and accessible therapy compared to T-cell engagers and monoclonal antibodies.

• Off-the-shelf approach overcomes manufacturing and accessibility challenges seen with traditional CAR T therapies.

• Multi-dosing and retreatment are possible due to the product's safety and off-the-shelf nature.

• Manufacturing capacity is robust, with a master cell bank enabling large-scale production and a GMP facility supporting up to 50,000 doses per year.

Clinical development and trial progress

• FT819 has shown strong efficacy and safety in early autoimmune trials, with some patients achieving durable remission and minimal hospitalization.

• Two regimens are being tested: regimen A (light conditioning with cyclophosphamide or bendamustine) and regimen B (no conditioning, on maintenance therapy).

• Both regimens are advancing, with regimen A being the most developed and regimen B undergoing dose-finding.

• Phase 1 trial is expected to complete early next year, with pivotal study initiation planned for the second half of next year.

• Hospitalization requirements are expected to be eliminated by year-end, enabling outpatient administration.

Regulatory and operational updates

• Received RMAT designation from the FDA, with productive and collaborative regulatory interactions.

• Both regimens are included in the RMAT pathway, and redosing will be allowed after primary endpoint achievement in pivotal trials.

• Site activation has accelerated, with eight sites currently active and plans to reach up to 20 by year-end, improving patient enrollment rates.

• Expansion into additional autoimmune indications (systemic sclerosis, vasculitis, myositis) is underway, with active patient screening.